Rigel Pharmaceuticals, Inc.
395 articles with Rigel Pharmaceuticals, Inc.
-
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
8/21/2020
Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to an employee's employment with Rigel, in accordance with NASDAQ Lis
-
Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program
8/4/2020
University of Amsterdam in vitro studies showed fostamatinib blocked macrophage hyper-inflammatory response to serum from severe COVID-19 patients
-
Rigel Announces Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Business Update
7/28/2020
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2020 financial results after market close on Tuesday, August 4 , 2020. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time ( 1:30pm Pacific Time ) to discuss
-
Rigel Announces Post-hoc Data Analysis of TAVALISSE® in Adult Patients with Immune Thrombocytopenia Published in the British Journal of Haematology
7/27/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that a paper presenting a post-hoc data analysis of TAVALISSE ® (fostamatinib disodium hexahydrate) tablets, as well as accompanying commentary have been published in the British Journal of Haematology. TAVALISSE, Rigel's oral spleen tyrosine kinase (SYK) inhibi
-
Clinical Catch-Up: July 13-17
7/20/2020
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
-
Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia
7/14/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib
-
Rigel Announces Availability of TAVLESSE® (Fostamatinib Disodium Hexahydrate) in Europe
7/9/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Grifols S.A., its collaborative partner in Europe , has launched TAVLESSE ® in Germany and the United Kingdom . It was approved by the European Commission in Janu
-
Rigel to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
6/17/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, is scheduled to present a company overview at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 at 10:30 a.m. Eastern Time . To access the live and subs
-
Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress
6/11/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE ® (fostamatinib disodium hexahydrate) tablets will be highlighted in a presentation at the Virtual Edition of the 25 th EHA Annual Congress taking place June 11-21, 2020 . The presentation will be made available on the event's web
-
Rigel to Present Four Posters Highlighting IRAK1/4 Inhibitor at the EULAR 2020 E-Congress
6/3/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to R835, the company's investigational IRAK1/4 inhibitor, will be presented in two oral and two poster presentations at the European League Against Rheumatism (EULAR) 2020 E-Congress taking place June 3-6, 2020 . A fifth abstract highlighting R83
-
Rigel to Present at the Jefferies 2020 Virtual Healthcare Conference
5/26/2020
Rigel Pharmaceuticals, Inc. announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:30 p.m. Eastern Time.
-
Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.
-
Rigel Reports First Quarter 2020 Financial Results and Provides Business Update
5/5/2020
Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2020, including sales of TAVALISSE® tablets, for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
-
Rigel Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
5/1/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that, due to public health and safety concerns related to the coronavirus ("COVID-19") pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others, it will host it
-
Rigel Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update
4/27/2020
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2020 financial results after market close on Tuesday, May 5 , 2020. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time ( 1:30pm Pacific Time ) to discuss th
-
Rigel Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
2/27/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2019, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
-
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2019 Financial Results
2/20/2020
Rigel Pharmaceuticals, Inc. announced that it will report its fourth quarter and year end 2019 financial results after market close on Thursday, February 27, 2020.
-
Rigel to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/9/2020
Rigel Pharmaceuticals, Inc. announced that Raul Rodriguez, the company's president and CEO, is scheduled to present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 7:30am PT in San Francisco, CA..
-
Rigel Announces Chief Commercial Officer Transition
12/17/2019
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that Eldon Mayer has resigned from his position as chief commercial officer effective December 23, 2019, to pursue an opportunity with an emerging company.